Regulatory roles of non-coding RNAs in colorectal cancer

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 19886-19919

  Wang, Jun ^a   Song, Yong Xi ^a   Ma, Bin ^a   Wang, Jia Jun ^a   Sun, Jing Xu ^a   Chen, Xiao Wan ^a   Zhao, Jun Hua ^a   Yang, Yu Chong ^a   Wang, Zhen Ning ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Colorectal cancer; Dysregulation; Non coding RNAs; Targets

Indexed keywords

ATM PROTEIN; BEVACIZUMAB; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CIRCULAR RNA; COLON CANCER ASSOCIATED TRANSCRIPT 1; COLON CANCER ASSOCIATED TRANSCRIPT 2; FLUOROPYRIMIDINE; HOX TRANSCRIPT ANTISENSE INTERGENIC RNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MICRORNA 182; MICRORNA 21; MICRORNA 223; MICRORNA 29A; PIWI INTERACTING RNA; PROTEIN MDM2; PROTEIN P53; RNA H19; SMALL INTERFERING RNA; SMALL NUCLEAR RNA; SMALL NUCLEOLAR RNA; TATA BINDING PROTEIN RELATED FACTOR; TELOMERASE REVERSE TRANSCRIPTASE; TENSIN; TRANSFER RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; COLORECTAL CANCER; DNA METHYLATION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; MRNA EXPRESSION ASSAY; NONHUMAN; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; RNA, UNTRANSLATED;

EID: 84939856898     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160819886     Document Type: Review

References (201)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004, 431, 931–945
2. Palazzo, A.F.; Lee, E.S. Non-coding RNA: What is functional and what is junk? Front. Genet. 2015, 6, doi:10.3389/fgene.2015.00002
3. Kaikkonen, M.U.; Lam, M.T.; Glass, C.K. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc. Res.2011, 90, 430–440
4. Li, M.; Izpisua Belmonte, J.C. Roles for noncoding RNAs in cell-fate determination and regeneration. Nat. Struct. Mol. Boil. 2015, 22, 2–4
5. Piccoli, M.T.; Gupta, S.K.; Thum, T. Noncoding RNAs as regulators of cardiomyocyte proliferation and death. J. Mol. Cell. Cardiol. 2015, doi:10.1016/j.yjmcc.2015.02.002
6. Huang, J.; Peng, J.; Guo, L. Non-Coding RNA: A new tool for the diagnosis, prognosis, and therapy of small cell lung cancer. J. Thorac. Oncol.2015, 10, 28–37
7. Ma, L.; Bajic, V.B.; Zhang, Z. On the classification of long non-coding RNAs. RNA Biol. 2013, 10, 925–933
8. Han, D.; Wang, M.; Ma, N.; Xu, Y.; Jiang, Y.; Gao, X. Long noncoding RNAs: Novel players in colorectal cancer. Cancer Lett.2015, 361, 13–21
9. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108
10. Allemani, C.; Weir, H.K.; Carreira, H.; Harewood, R.; Spika, D.; Wang, X.S.; Bannon, F.; Ahn, J.V.; Johnson, C.J.; Bonaventure, A., et al. Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015, 385, 977–1010
11. Wang, J.; Song, Y.X.; Wang, Z.N. Non-coding RNAs in gastric cancer. Gene 2015, 560, 1–8
12. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854
13. Amirkhah, R.; Schmitz, U.; Linnebacher, M.; Wolkenhauer, O.; Farazmand, A. MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes Cancer 2015, 54, 129–141
14. Tokarz, P.; Blasiak, J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim. Pol. 2012, 59, 467–474
15. Hur, K. MicroRNAs: Promising biomarkers for diagnosis and therapeutic targets in human colorectal cancer metastasis. BMB Rep. 2015, 48, 217–222
16. Hollis, M.; Nair, K.; Vyas, A.; Chaturvedi, L.S.; Gambhir, S.; Vyas, D. MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J. Gastroenterol. 2015, 21, 8284–8292
17. Rossi, S.; di Narzo, A.F.; Mestdagh, P.; Jacobs, B.; Bosman, F.T.; Gustavsson, B.; Majoie, B.; Roth, A.; Vandesompele, J.; Rigoutsos, I., et al.MicroRNAs in colon cancer: A roadmap for discovery. FEBS Lett. 2012, 586, 3000–3007
18. Okugawa, Y.; Toiyama, Y.; Goel, A. An update on microRNAs as colorectal cancer biomarkers: Where are we and what’s next? Expert Rev. Mol. Diagn. 2014, 14, 999–1021
19. Tao, J.; Wu, D.; Li, P.; Xu, B.; Lu, Q.; Zhang, W. MicroRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol. Med. Rep.2012, 5, 167–172
20. Morimura, R.; Komatsu, S.; Ichikawa, D.; Takeshita, H.; Tsujiura, M.; Nagata, H.; Konishi, H.; Shiozaki, A.; Ikoma, H.; Okamoto, K., et al.Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br. J. Cancer 2011, 105, 1733–1740
21. Wu, C.W.; Dong, Y.J.; Liang, Q.Y.; He, X.Q.; Ng, S.S.; Chan, F.K.; Sung, J.J.; Yu, J. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS ONE 2013, 8, e57036
22. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K., et al.Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002, 8, 793–800
23. Zhu, J.; Chen, L.; Zou, L.; Yang, P.; Wu, R.; Mao, Y.; Zhou, H.; Li, R.; Wang, K.; Wang, W., et al.miR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum. Immunol. 2014, 75, 348–353
24. Yang, Y.; Yang, J.J.; Tao, H.; Jin, W.S. MicroRNA-21 controls hTERT via PTEN in human colorectal cancer cell proliferation. J. Physiol. Biochem. 2015, 71, 59–68
25. Yamamichi, N.; Shimomura, R.; Inada, K.; Sakurai, K.; Haraguchi, T.; Ozaki, Y.; Fujita, S.; Mizutani, T.; Furukawa, C.; Fujishiro, M., et al.Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin. Cancer Res.2009, 15, 4009–4016
26. Oue, N.; Anami, K.; Schetter, A.J.; Moehler, M.; Okayama, H.; Khan, M.A.; Bowman, E.D.; Mueller, A.; Schad, A.; Shimomura, M., et al.High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int. J. Cancer 2014, 134, 1926–1934
27. Chen, T.; Yao, L.Q.; Shi, Q.; Ren, Z.; Ye, L.C.; Xu, J.M.; Zhou, P.H.; Zhong, Y.S. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1). Cancer Biol. Ther. 2014, 15, 516–523
28. Xu, R.S.; Wu, X.D.; Zhang, S.Q.; Li, C.F.; Yang, L.; Li, D.D.; Zhang, B.G.; Zhang, Y.; Jin, J.P.; Zhang, B. The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer. Int. J. Oncol. 2013, 42, 676–682
29. Sun, D.; Yu, F.; Ma, Y.; Zhao, R.; Chen, X.; Zhu, J.; Zhang, C.Y.; Chen, J.; Zhang, J. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J. Biol. Chem. 2013, 288, 9508–9518
30. Zhang, G.; Zhou, H.; Xiao, H.; Liu, Z.; Tian, H.; Zhou, T. MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig. Dis. Sci.2014, 59, 98–107
31. Zhou, T.; Zhang, G.; Liu, Z.; Xia, S.; Tian, H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int. J. Colorectal Dis. 2013, 28, 19–24
32. Tang, W.; Zhu, Y.; Gao, J.; Fu, J.; Liu, C.; Liu, Y.; Song, C.; Zhu, S.; Leng, Y.; Wang, G., et al.MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br. J. Cancer 2014, 110, 450–458
33. Wu, W.; Yang, J.; Feng, X.; Wang, H.; Ye, S.; Yang, P.; Tan, W.; Wei, G.; Zhou, Y. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol. Cancer 2013, 12, doi:10.1186/1476-4598-12-30
34. Huang, Z.; Huang, S.; Wang, Q.; Liang, L.; Ni, S.; Wang, L.; Sheng, W.; He, X.; Du, X. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res. 2011, 71, 2582–2589
35. Gao, F.; Wang, W. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol. Med. Rep. 2015, 11, 1200–1206
36. Geng, L.; Sun, B.; Gao, B.; Wang, Z.; Quan, C.; Wei, F.; Fang, X.D. MicroRNA-103 promotes colorectal cancer by targeting tumor suppressor DICER and PTEN. Int. J Mol. Sci. 2014, 15, 8458–8472
37. Ji, D.; Chen, Z.; Li, M.; Zhan, T.; Yao, Y.; Zhang, Z.; Xi, J.; Yan, L.; Gu, J. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol. Cancer 2014, 13, doi:10.1186/1476-4598-13-86
38. Wei, Z.; Cui, L.; Mei, Z.; Liu, M.; Zhang, D. miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway. FEBS Lett. 2014, 588, 1773–1779
39. Liu, H.; Du, L.; Wen, Z.; Yang, Y.; Li, J.; Wang, L.; Zhang, X.; Liu, Y.; Dong, Z.; Li, W., et al.Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int. J. Colorectal Dis. 2013, 28, 697–703
40. Mo, J.S.; Alam, K.J.; Kang, I.H.; Park, W.C.; Seo, G.S.; Choi, S.C.; Kim, H.S.; Moon, H.B.; Yun, K.J.; Chae, S.C. MicroRNA 196B regulates FAS-mediated apoptosis in colorectal cancer cells. Oncotarget 2015, 6, 2843–2855
41. Zhang, J.; Luo, X.; Li, H.; Yue, X.; Deng, L.; Cui, Y.; Lu, Y. MicroRNA-223 functions as an oncogene in human colorectal cancer cells. Oncol. Rep. 2014, 32, 115–120
42. Tsang, W.P.; Kwok, T.T. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009, 30, 953–959
43. Zheng, K.; Liu, W.; Liu, Y.; Jiang, C.; Qian, Q. MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol. Lett. 2015, 9, 869–874
44. Wang, H.; An, H.; Wang, B.; Liao, Q.; Li, W.; Jin, X.; Cui, S.; Zhang, Y.; Ding, Y.; Zhao, L. miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway. Eur. J. Cancer 2013, 49, 3924–3935
45. Xiang, K.M.; Li, X.R. miR-133b acts as a tumor suppressor and negatively regulates TBPL1 in colorectal cancer cells. Asian Pac. J. Cancer Prev. 2014, 15, 3767–3772
46. Duan, F.T.; Qian, F.; Fang, K.; Lin, K.Y.; Wang, W.T.; Chen, Y.Q. miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. Mol. Cancer 2013, 12, doi: 10.1186/1476-4598-12-164
47. Zhao, H.J.; Ren, L.L.; Wang, Z.H.; Sun, T.T.; Yu, Y.N.; Wang, Y.C.; Yan, T.T.; Zou, W.; He, J.; Zhang, Y., et al.miR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. Theranostics 2014, 4, 1193–1208
48. Wang, B.; Shen, Z.L.; Gao, Z.D.; Zhao, G.; Wang, C.Y.; Yang, Y.; Zhang, J.Z.; Yan, Y.C.; Shen, C.; Jiang, K.W., et al. miR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle 2015, 14, 1046–1058
49. Fish, J.E.; Santoro, M.M.; Morton, S.U.; Yu, S.; Yeh, R.F.; Wythe, J.D.; Ivey, K.N.; Bruneau, B.G.; Stainier, D.Y.; Srivastava, D. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15, 272–284
50. Li, X.M.; Wang, A.M.; Zhang, J.; Yi, H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med. Oncol. 2011, 28, 1054–1057
51. Zhou, Y.; Feng, X.; Liu, Y.L.; Ye, S.C.; Wang, H.; Tan, W.K.; Tian, T.; Qiu, Y.M.; Luo, H.S. Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS ONE 2013, 8, e81203
52. Zhang, Y.; Wang, X.; Xu, B.; Wang, B.; Wang, Z.; Liang, Y.; Zhou, J.; Hu, J.; Jiang, B. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol. Rep. 2013, 30, 1976–1984
53. Liu, Y.; Zhou, Y.; Feng, X.; An, P.; Quan, X.; Wang, H.; Ye, S.; Yu, C.; He, Y.; Luo, H. MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways. Int. J. Oncol. 2014, 44, 203–210
54. Peng, H.; Luo, J.; Hao, H.; Hu, J.; Xie, S.K.; Ren, D.; Rao, B. MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. Oncol. Rep. 2014, 31, 2055–2062
55. Wang, M.J.; Li, Y.; Wang, R.; Wang, C.; Yu, Y.Y.; Yang, L.; Zhang, Y.; Zhou, B.; Zhou, Z.G.; Sun, X.F. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. Int. J. Colorectal Dis. 2013, 28, 183–189
56. Zhang, J.; Lu, Y.; Yue, X.; Li, H.; Luo, X.; Wang, Y.; Wang, K.; Wan, J. miR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS ONE 2013, 8, e70300
57. Shen, K.; Liang, Q.; Xu, K.; Cui, D.; Jiang, L.; Yin, P.; Lu, Y.; Li, Q.; Liu, J. miR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem. Pharmacol. 2012, 84, 320–330
58. Zhang, L.; Dong, Y.; Zhu, N.; Tsoi, H.; Zhao, Z.; Wu, C.W.; Wang, K.; Zheng, S.; Ng, S.S.; Chan, F.K., et al.MicroRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Mol. Cancer 2014, 13, doi:10.1186/1476-4598-13-124
59. Feng, Y.; Zhu, J.; Ou, C.; Deng, Z.; Chen, M.; Huang, W.; Li, L. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br. J. Cancer 2014, 110, 2300–2309
60. Song, Y.; Xu, Y.; Wang, Z.; Chen, Y.; Yue, Z.; Gao, P.; Xing, C.; Xu, H. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int. J. Cancer 2012, 131, 1042–1051
61. Wang, X.W.; Xi, X.Q.; Wu, J.; Wan, Y.Y.; Hui, H.X.; Cao, X.F. MicroRNA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH3 in colorectal cancer. Oncol. Rep. 2015, 33, 1402–1410
62. Chen, D.L.; Wang, Z.Q.; Zeng, Z.L.; Wu, W.J.; Zhang, D.S.; Luo, H.Y.; Wang, F.; Qiu, M.Z.; Wang, D.S.; Ren, C., et al.Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014, 60, 598–609
63. He, X.; Dong, Y.; Wu, C.W.; Zhao, Z.; Ng, S.S.; Chan, F.K.; Sung, J.J.; Yu, J. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol. Med. 2012, 18, 1491–1498
64. Ke, T.W.; Hsu, H.L.; Wu, Y.H.; Chen, W.T.; Cheng, Y.W.; Cheng, C.W. MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. Dis. Markers 2014, 2014, doi:10.1155/2014/617150
65. Zhao, H.; Dong, T.; Zhou, H.; Wang, L.; Huang, A.; Feng, B.; Quan, Y.; Jin, R.; Zhang, W.; Sun, J., et al.miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis 2014, 35, 886–895
66. Sun, J.Y.; Huang, Y.; Li, J.P.; Zhang, X.; Wang, L.; Meng, Y.L.; Yan, B.; Bian, Y.Q.; Zhao, J.; Wang, W.Z., et al.MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem. Biophys. Res. Commun. 2012, 420, 787–792
67. Wang, H.; Wu, J.; Meng, X.; Ying, X.; Zuo, Y.; Liu, R.; Pan, Z.; Kang, T.; Huang, W. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 2011, 32, 1033–1042
68. Wang, Y.; Tang, Q.; Li, M.; Jiang, S.; Wang, X. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem. Biophys. Res. Commun. 2014, 444, 199–204
69. Zhang, G.J.; Zhou, H.; Xiao, H.X.; Li, Y.; Zhou, T. miR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer 2014, 14, doi:10.1186/1471-2407-14-109
70. Sun, Y.; Shen, S.; Liu, X.; Tang, H.; Wang, Z.; Yu, Z.; Li, X.; Wu, M. miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol. Cell. Biochem. 2014, 390, 19–30
71. Chai, J.; Wang, S.; Han, D.; Dong, W.; Xie, C.; Guo, H. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Boil.2015, 36, 1313–1321
72. Ma, K.; Pan, X.; Fan, P.; He, Y.; Gu, J.; Wang, W.; Zhang, T.; Li, Z.; Luo, X. Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol. Cancer 2014, 13, 118
73. Xuan, Y.; Yang, H.; Zhao, L.; Lau, W.B.; Lau, B.; Ren, N.; Hu, Y.; Yi, T.; Zhao, X.; Zhou, S., et al.MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Lett.2015, 360, 89–105
74. Di Lena, M.; Travaglio, E.; Altomare, D.F. New strategies for colorectal cancer screening. World J. Gastroenterol. 2013, 19, 1855–1860
75. Ahmed, F.E.; Ahmed, N.C.; Vos, P.W.; Bonnerup, C.; Atkins, J.N.; Casey, M.; Nuovo, G.J.; Naziri, W.; Wiley, J.E.; Mota, H., et al.Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genom. Proteom. 2013, 10, 93–113
76. Yau, T.O.; Wu, C.W.; Dong, Y.; Tang, C.M.; Ng, S.S.; Chan, F.K.; Sung, J.J.; Yu, J. MicroRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br. J. Cancer 2014, 111, 1765–1771
77. Phua, L.C.; Chue, X.P.; Koh, P.K.; Cheah, P.Y.; Chan, E.C.; Ho, H.K. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. Oncol. Rep. 2014, 32, 97–104
78. Wu, C.W.; Ng, S.S.; Dong, Y.J.; Ng, S.C.; Leung, W.W.; Lee, C.W.; Wong, Y.N.; Chan, F.K.; Yu, J.; Sung, J.J. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012, 61, 739–745
79. Koga, Y.; Yamazaki, N.; Yamamoto, Y.; Yamamoto, S.; Saito, N.; Kakugawa, Y.; Otake, Y.; Matsumoto, M.; Matsumura, Y. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol. Biomark. Prev. 2013, 22, 1844–1852
80. Wu, C.W.; Ng, S.C.; Dong, Y.; Tian, L.; Ng, S.S.; Leung, W.W.; Law, W.T.; Yau, T.O.; Chan, F.K.; Sung, J.J.; Yu, J. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin. Cancer Res. 2014, 20, 2994–3002
81. Kalimutho, M.; del Vecchio Blanco, G.; di Cecilia, S.; Sileri, P.; Cretella, M.; Pallone, F.; Federici, G.; Bernardini, S. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J. Gastroenterol. 2011, 46, 1391–1402
82. Wu, X.D.; Song, Y.C.; Cao, P.L.; Zhang, H.; Guo, Q.; Yan, R.; Diao, D.M.; Cheng, Y.; Dang, C.X. Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. Med. Oncol. 2014, 31, 1–6
83. Li, J.M.; Zhao, R.H.; Li, S.T.; Xie, C.X.; Jiang, H.H.; Ding, W.J.; Du, P.; Chen, W.; Yang, M.; Cui, L. Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med. J. 2012, 33, 24–29
84. Ghanbari, R.; Mosakhani, N.; Asadi, J.; Nouraee, N.; Mowla, S. J.; Poustchi, H.; Malekzadeh, R.; Knuutila, S. Decreased expression of fecal miR-4478 and miR-1295b-3p in early-stage colorectal cancer. Cancer Biomark. 2014, 15, 189–195
85. Luo, X.; Stock, C.; Burwinkel, B.; Brenner, H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE 2013, 8, e62880
86. Pu, X.X.; Huang, G.L.; Guo, H.Q.; Guo, C.C.; Li, H.; Ye, S.; Ling, S.; Jiang, L.; Tian, Y.; Lin, T.Y. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 2010, 25, 1674–1680
87. Toiyama, Y.; Takahashi, M.; Hur, K.; Nagasaka, T.; Tanaka, K.; Inoue, Y.; Kusunoki, M.; Boland, C.R.; Goel, A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst. 2013, 105, 849–859
88. Basati, G.; Emami Razavi, A.; Abdi, S.; Mirzaei, A. Elevated level of microRNA-21 in the serum of patients with colorectal cancer. Med. Oncol. 2014, 31, 1–5
89. Menendez, P.; Padilla, D.; Villarejo, P.; Palomino, T.; Nieto, P.; Menendez, J.M.; Rodriguez-Montes, J.A. Prognostic implications of serum microRNA-21 in colorectal cancer. J. Surg. Oncol.2013, 108, 369–373
90. Yuan, D.; Li, K.; Zhu, K.; Yan, R.; Dang, C. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol. Ther. 2015, 16, 268–275
91. Zhang, L.; Meng, L.; Fan, Z.; Liu, B.; Pei, Y.; Zhao, Z. Expression of plasma miR-106a in colorectal cancer and its clinical significance. J. Southern Med. Univ. 2014, 34, 354–357
92. Chen, Q.; Xia, H.W.; Ge, X.J.; Zhang, Y.C.; Tang, Q.L.; Bi, F. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac. J. Cancer Prev. 2013, 14, 7421–7426
93. Brunet Vega, A.; Pericay, C.; Moya, I.; Ferrer, A.; Dotor, E.; Pisa, A.; Casalots, A.; Serra-Aracil, X.; Oliva, J. C.; Ruiz, A., et al.MicroRNA expression profile in stage III colorectal cancer: Circulating miR-18a and miR-29a as promising biomarkers. Oncol. Rep. 2013, 30, 320–326
94. Yang, X.; Zhong, J.; Ji, Y.; Li, J.; Jian, Y.; Zhang, J.; Yang, W. The expression and clinical significance of microRNAs in colorectal cancer detecting. Tumour Biol.2014, 36, 2675–2684
95. Liu, Y.; Zhou, Y.; Feng, X.; Yang, P.; Yang, J.; An, P.; Wang, H.; Ye, S.; Yu, C.; He, Y., et al.Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer 2014, 53, 358–365
96. Chu, D.; Zheng, J.; Li, J.; Li, Y.; Zhang, J.; Zhao, Q.; Wang, W.; Ji, G. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumour Biol.2014, 35, 9787–9792
97. Yang, X.; Zeng, Z.; Hou, Y.; Yuan, T.; Gao, C.; Jia, W.; Yi, X.; Liu, M. MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: A systematic review and meta-analysis. PLoS ONE 2014, 9, e88745
98. Fang, L.; Li, H.; Wang, L.; Hu, J.; Jin, T.; Wang, J.; Yang, B.B. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014, 5, 2974–2987
99. Zhao, Z.; He, J.; Zhang, J.; Liu, M.; Yang, S.; Li, N.; Li, X. Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer. Tumour Biol.2014, 35, 5227–5235
100. Diaz, T.; Tejero, R.; Moreno, I.; Ferrer, G.; Cordeiro, A.; Artells, R.; Navarro, A.; Hernandez, R.; Tapia, G.; Monzo, M. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J. Surg. Oncol.2014, 109, 676–683
101. Zhang, Y.; Geng, L.; Talmon, G.; Wang, J. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J. Biol. Chem. 2015, 290, 6215–6225
102. Zhang, Y.; Zheng, L.; Huang, J.; Gao, F.; Lin, X.; He, L.; Li, D.; Li, Z.; Ding, Y.; Chen, L. miR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS ONE 2014, 9, e93917
103. Xue, Q.; Sun, K.; Deng, H.J.; Lei, S.T.; Dong, J.Q.; Li, G.X. Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN. World J. Gastroenterol. 2013, 19, 9307–9317
104. Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D. STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene 2014, doi:10.1038/onc.2014
105. Wu, L.; Yu, H.; Zhao, Y.; Zhang, C.; Wang, J.; Yue, X.; Yang, Q.; Hu, W. HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget 2015, 6, 4406–4417
106. Lu, W.; Fu, Z.; Wang, H.; Feng, J.; Wei, J.; Guo, J. Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/β-catenin signaling. Cancer Lett.2014, 343, 190–199
107. Levin, H.L.; Moran, J.V. Dynamic interactions between transposable elements and their hosts. Nat. Rev. Genet. 2011, 12, 615–627
108. Sato, K.; Siomi, M.C. Piwi-interacting RNAs: biological functions and biogenesis. Essays Biochem. 2013, 54, 39–52
109. Assumpcao, C.B.; Calcagno, D.Q.; Araujo, T.M.; Batista dos Santos, S.E.; Ribeiro dos Santos, A.K.; Riggins, G.J.; Burbano, R.R.; Assumpcao, P.P. The role of piRNA and its potential clinical implications in cancer. Epigenomics 2015, 1–10
110. Moyano, M.; Stefani, G. PiRNA involvement in genome stability and human cancer. J. Hematol. Oncol. 2015, 8, doi:10.1186/s13045-015-0133-5
111. Cheng, J.; Guo, J.M.; Xiao, B.X.; Miao, Y.; Jiang, Z.; Zhou, H.; Li, Q.N. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clin. Chim. Acta 2011, 412, 1621–1625
112. Chu, H.; Xia, L.; Qiu, X.; Gu, D.; Zhu, L.; Jin, J.; Hui, G.; Hua, Q.; Du, M.; Tong, N., et al.Genetic variants in noncoding PIWI-interacting RNA and colorectal cancer risk. Cancer 2015, 121, 2044–2052
113. Xu, M.D.; Qi, P.; Du, X. Long non-coding RNAs in colorectal cancer: Implications for pathogenesis and clinical application. Mod. Pathol. 2014, 27, 1310–1320
114. Ye, L.C.; Zhu, X.; Qiu, J.J.; Xu, J.; Wei, Y. Involvement of long non-coding RNA in colorectal cancer: From benchtop to bedside (Review). Oncol. Lett. 2015, 9, 1039–1045
115. Li, C.H.; Chen, Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int. J. Biochem. Cell Biol. 2013, 45, 1895–1910
116. Ling, H.; Vincent, K.; Pichler, M.; Fodde, R.; Berindan-Neagoe, I.; Slack, F.J.; Calin, G.A. Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene 2015. doi:87310.1038/onc.2014
117. Xue, Y.; Ma, G.; Gu, D.; Zhu, L.; Hua, Q.; Du, M.; Chu, H.; Tong, N.; Chen, J.; Zhang, Z.; Wang, M. Genome-wide analysis of long noncoding RNA signature in human colorectal cancer. Gene 2015, 556, 227–234
118. Han, J.; Rong, L.F.; Shi, C.B.; Dong, X.G.; Wang, J.; Wang, B.L.; Wen, H.; He, Z.Y. Screening of lymph nodes metastasis associated lncRNAs in colorectal cancer patients. World J Gastroenterol. 2014, 20, 8139–8150
119. Dong, Y.; Liang, G.; Yuan, B.; Yang, C.; Gao, R.; Zhou, X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 2014, 36, 1477–1486
120. Lai, M.C.; Yang, Z.; Zhou, L.; Zhu, Q.Q.; Xie, H.Y.; Zhang, F.; Wu, L.M.; Chen, L.M.; Zheng, S.S. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med. Oncol. 2012, 29, 1810–1816
121. Hu, L.; Wu, Y.; Tan, D.; Meng, H.; Wang, K.; Bai, Y.; Yang, K. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2015, 34, doi:10.1186/s13046-015-0123-z.
122. Zheng, H.T.; Shi, D.B.; Wang, Y.W.; Li, X.X.; Xu, Y.; Tripathi, P.; Gu, W.L.; Cai, G.X.; Cai, S.J. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int. J. Clin. Exp. Pathol. 2014, 7, 3174–3181
123. Ji, Q.; Zhang, L.; Liu, X.; Zhou, L.; Wang, W.; Han, Z.; Sui, H.; Tang, Y.; Wang, Y.; Liu, N., et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br. J. Cancer 2014, 111, 736–748
124. Xu, C.; Yang, M.; Tian, J.; Wang, X.; Li, Z. MALAT-1: A long non-coding RNA and its important 3′ end functional motif in colorectal cancer metastasis. Int. J. Oncol.2011, 39, 169–175
125. Yang, M.H.; Hu, Z.Y.; Xu, C.; Xie, L.Y.; Wang, X.Y.; Chen, S.Y.; Li, Z.G. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim. Biophys. Acta 2015, 1852, 166–174
126. Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274–283
127. Carter, L.G.; D’Orazio, J.A.; Pearson, K.J. Resveratrol and cancer: Focus on in vivo evidence. Endocr. Relat. Cancer 2014, 21, R209–R225
128. Liu, B.; Zhou, Z.; Zhou, W.; Liu, J.; Zhang, Q.; Xia, J.; Liu, J.; Chen, N.; Li, M.; Zhu, R. Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest and apoptosis through caspase/cyclinCDK pathways. Mol. Med. Rep. 2014, 10, 1697–1702
129. Ji, Q.; Liu, X.; Han, Z.; Zhou, L.; Sui, H.; Yan, L.; Jiang, H.; Ren, J.; Cai, J.; Li, Q. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression. BMC Cancer 2015, 15, doi:10.1186/s12885-015-1119-y.
130. Ji, Q.; Liu, X.; Fu, X.; Zhang, L.; Sui, H.; Zhou, L.; Sun, J.; Cai, J.; Qin, J.; Ren, J., et al.Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS ONE 2013, 8, e78700
131. Cai, B.; Song, X.Q.; Cai, J.P.; Zhang, S. HOTAIR: A cancer-related long non-coding RNA. Neoplasma 2014, 61, 379–391
132. Hajjari, M.; Salavaty, A. HOTAIR: An oncogenic long non-coding RNA in different cancers. Cancer Biol. Med. 2015, 12, 1–9
133. Cai, B.; Wu, Z.; Liao, K.; Zhang, S. Long noncoding RNA HOTAIR can serve as a common molecular marker for lymph node metastasis: A meta-analysis. Tumour Biol.2014, 35, 8445–8450
134. Deng, Q.; Sun, H.; He, B.; Pan, Y.; Gao, T.; Chen, J.; Ying, H.; Liu, X.; Wang, F.; Xu, Y.; Wang, S. Prognostic value of long non-coding RNA HOTAIR in various cancers. PLoS ONE 2014, 9, e110059
135. Yao, Y.; Li, J.; Wang, L. Large intervening non-coding RNA HOTAIR is an indicator of poor prognosis and a therapeutic target in human cancers. Int. J. Mol. Sci. 2014, 15, 18985–18999
136. Wang, S.; Wang, Z. Prognostic value of long noncoding RNA HOTAIR in digestive system malignancies. J. Gastroenterol. Hepatol. 2015, 30, 1123–1133
137. Xue, Y.; Gu, D.; Ma, G.; Zhu, L.; Hua, Q.; Chu, H.; Tong, N.; Chen, J.; Zhang, Z.; Wang, M. Genetic variants in lncRNA HOTAIR are associated with risk of colorectal cancer. Mutagenesis 2015, 30, 303–310
138. Kogo, R.; Shimamura, T.; Mimori, K.; Kawahara, K.; Imoto, S.; Sudo, T.; Tanaka, F.; Shibata, K.; Suzuki, A.; Komune, S., et al.Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011, 71, 6320–6326
139. Wu, Z.H.; Wang, X.L.; Tang, H.M.; Jiang, T.; Chen, J.; Lu, S.; Qiu, G.Q.; Peng, Z.H.; Yan, D.W. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol. Rep. 2014, 32, 395–402
140. Svoboda, M.; Slyskova, J.; Schneiderova, M.; Makovicky, P.; Bielik, L.; Levy, M.; Lipska, L.; Hemmelova, B.; Kala, Z.; Protivankova, M., et al.HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 2014, 35, 1510–1515
141. Lustig, O.; Ariel, I.; Ilan, J.; Lev-Lehman, E.; De-Groot, N.; Hochberg, A. Expression of the imprinted gene H19 in the human fetus. Mol. Reprod. Dev. 1994, 38, 239–246
142. Cui, H.; Onyango, P.; Brandenburg, S.; Wu, Y.; Hsieh, C.L.; Feinberg, A.P. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002, 62, 6442–6446
143. Tian, F.; Tang, Z.; Song, G.; Pan, Y.; He, B.; Bao, Q.; Wang, S. Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients. Mol. Med. Rep. 2012, 5, 1536–1540
144. Matouk, I.J.; Raveh, E.; Abu-lail, R.; Mezan, S.; Gilon, M.; Gershtain, E.; Birman, T.; Gallula, J.; Schneider, T.; Barkali, M.; Richler, C., et al.Oncofetal H19 RNA promotes tumor metastasis. Biochim. Biophys. Acta 2014, 1843, 1414–1426
145. Tsang, W.P.; Ng, E.K.; Ng, S.S.; Jin, H.; Yu, J.; Sung, J.J.; Kwok, T.T. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010, 31, 350–358
146. Nissan, A.; Stojadinovic, A.; Mitrani-Rosenbaum, S.; Halle, D.; Grinbaum, R.; Roistacher, M.; Bochem, A.; Dayanc, B. E.; Ritter, G.; Gomceli, I., et al.Colon cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissues. Int. J. Cancer. 2012, 130, 1598–1606
147. Alaiyan, B.; Ilyayev, N.; Stojadinovic, A.; Izadjoo, M.; Roistacher, M.; Pavlov, V.; Tzivin, V.; Halle, D.; Pan, H.; Trink, B., et al.Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence. BMC Cancer2013, 13, doi:10.1186/1471-2407-13-196
148. Kam, Y.; Rubinstein, A.; Naik, S.; Djavsarov, I.; Halle, D.; Ariel, I.; Gure, A.O.; Stojadinovic, A.; Pan, H.; Tsivin, V., et al.Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. Cancer Lett. 2014, 352, 90–96
149. Xiang, J.F.; Yin, Q.F.; Chen, T.; Zhang, Y.; Zhang, X.O.; Wu, Z.; Zhang, S.; Wang, H.B.; Ge, J.; Lu, X., et al.Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014, 24, 513–531
150. Ling, H.; Spizzo, R.; Atlasi, Y.; Nicoloso, M.; Shimizu, M.; Redis, R.S.; Nishida, N.; Gafa, R.; Song, J.; Guo, Z., et al.CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013, 23, 1446–1461
151. Redis, R.S.; Sieuwerts, A.M.; Look, M.P.; Tudoran, O.; Ivan, C.; Spizzo, R.; Zhang, X.; de Weerd, V.; Shimizu, M.; Ling, H., et al.CCAT2, a novel long non-coding RNA in breast cancer: Expression study and clinical correlations. Oncotarget 2013, 4, 1748–1762
152. Qiu, M.; Xu, Y.; Yang, X.; Wang, J.; Hu, J.; Xu, L.; Yin, R. CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumour Biol.2014, 35, 5375–5380
153. Qi, P.; Xu, M.D.; Ni, S.J.; Huang, D.; Wei, P.; Tan, C.; Zhou, X.Y.; Du, X. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J. Transl. Med. 2013, 11, doi:10.1186/1479-5876-11-122
154. Liu, Q.; Huang, J.; Zhou, N.; Zhang, Z.; Zhang, A.; Lu, Z.; Wu, F.; Mo, Y.Y. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 2013, 41, 4976–4987
155. Sana, J.; Hankeova, S.; Svoboda, M.; Kiss, I.; Vyzula, R.; Slaby, O. Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer. Oncology 2012, 82, 114–118
156. Wang, G.; Li, Z.; Zhao, Q.; Zhu, Y.; Zhao, C.; Li, X.; Ma, Z.; Li, X.; Zhang, Y. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. Oncol. Rep. 2014, 31, 1839–1845
157. Zhai, H.; Fesler, A.; Schee, K.; Fodstad, O.; Flatmark, K.; Ju, J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin. Colorectal Cancer 2013, 12, 261–266
158. Yin, D.; He, X.; Zhang, E.; Kong, R.; De, W.; Zhang, Z. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med. Oncol. 2014, 31, 1–8
159. Qi, P.; Xu, M.D.; Ni, S.J.; Shen, X.H.; Wei, P.; Huang, D.; Tan, C.; Sheng, W.Q.; Zhou, X.Y.; Du, X. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol. Carcinog.2015, 54, 742–750
160. Yan, B.; Gu, W.; Yang, Z.; Gu, Z.; Yue, X.; Gu, Q.; Liu, L. Downregulation of a long noncoding RNA-ncRuPAR contributes to tumor inhibition in colorectal cancer. Tumour Biol.2014, 35, 11329–11335
161. Yin, D.D.; Liu, Z.J.; Zhang, E.; Kong, R.; Zhang, Z.H.; Guo, R.H. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol.2015, 36, 4851–4859
162. Shi, D.; Zheng, H.; Zhuo, C.; Peng, J.; Li, D.; Xu, Y.; Li, X.; Cai, G.; Cai, S. Low expression of novel lncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer. Med. Oncol. 2014, 31, 1–9
163. Li, L.; Sun, R.; Liang, Y.; Pan, X.; Li, Z.; Bai, P.; Zeng, X.; Zhang, D.; Zhang, L.; Gao, L. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J. Exp. Clin. Cancer Res. 2013, 32, doi:10.1186/1756-9966-32-104
164. Takahashi, Y.; Sawada, G.; Kurashige, J.; Uchi, R.; Matsumura, T.; Ueo, H.; Takano, Y.; Eguchi, H.; Sudo, T.; Sugimachi, K., et al.Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br. J. Cancer 2014, 110, 164–171
165. Ellis, B.C.; Graham, L.D.; Molloy, P.L. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim. Biophys. Acta 2014, 1843, 372–386
166. Graham, L.D.; Pedersen, S.K.; Brown, G.S.; Ho, T.; Kassir, Z.; Moynihan, A.T.; Vizgoft, E.K.; Dunne, R.; Pimlott, L.; Young, G.P., et al.Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer 2011, 2, 829–840
167. Matouk, I.J.; Abbasi, I.; Hochberg, A.; Galun, E.; Dweik, H.; Akkawi, M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur. J. Gastroenterol. Hepatol. 2009, 21, 688–692
168. Ge, X.; Chen, Y.; Liao, X.; Liu, D.; Li, F.; Ruan, H.; Jia, W. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med. Oncol. 2013, 30, 588
169. Guo, Q.; Zhao, Y.; Chen, J.; Hu, J.; Wang, S.; Zhang, D.; Sun, Y. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol. Lett.2014, 8, 869–875
170. Shi, Y.; Liu, Y.; Wang, J.; Jie, D.; Yun, T.; Li, W.; Yan, L.; Wang, K.; Feng, J. Downregulated Long noncoding RNA BANCR promotes the proliferation of colorectal cancer cells via downregualtion of p21 expression. PLoS ONE 2015, 10, e0122679
171. Han, Y.; Yang, Y.N.; Yuan, H.H.; Zhang, T.T.; Sui, H.; Wei, X.L.; Liu, L.; Huang, P.; Zhang, W.J.; Bai, Y.X. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 2014, 46, 396–401
172. Iguchi, T.; Uchi, R.; Nambara, S.; Saito, T.; Komatsu, H.; Hirata, H.; Ueda, M.; Sakimura, S.; Takano, Y.; Kurashige, J., et al.A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res.2015, 35, 1385–1388
173. Qiu, J.J.; Yan, J.B. Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer. Tumour Biol.2015, doi:10.1007/s13277-015-3448-5
174. Ma, Y.; Yang, Y.; Wang, F.; Moyer, M.P.; Wei, Q.; Zhang, P.; Yang, Z.; Liu, W.; Zhang, H.; Chen, N., et al.Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. Gut 2015. doi:10.1136/gutjnl-2014–308392
175. Kiss-Laszlo, Z.; Henry, Y.; Bachellerie, J.P.; Caizergues-Ferrer, M.; Kiss, T. Site-specific ribose methylation of preribosomal RNA: A novel function for small nucleolar RNAs. Cell 1996, 85, 1077–1088
176. Kiss-Laszlo, Z.; Henry, Y.; Kiss, T. Sequence and structural elements of methylation guide snoRNAs essential for site-specific ribose methylation of pre-rRNA. EMBO J. 1998, 17, 797–807
177. Kiss, A.M.; Jady, B.E.; Bertrand, E.; Kiss, T. Human box H/ACA pseudouridylation guide RNA machinery. Mol. Cell. Biol.2004, 24, 5797–5807
178. McMahon, M.; Contreras, A.; Ruggero, D. Small RNAs with big implications: New insights into H/ACA snoRNA function and their role in human disease. Wiley Interdiscip. Rev. RNA 2015, 6, 173–189
179. Appaiah, H.N.; Goswami, C.P.; Mina, L.A.; Badve, S.; Sledge, G.W., Jr.; Liu, Y.; Nakshatri, H. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2943
180. Dong, X.Y.; Rodriguez, C.; Guo, P.; Sun, X.; Talbot, J.T.; Zhou, W.; Petros, J.; Li, Q.; Vessella, R.L.; Kibel, A.S., et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum. Mol. Genet. 2008, 17, 1031–1042
181. Gao, L.; Ma, J.; Mannoor, K.; Guarnera, M.A.; Shetty, A.; Zhan, M.; Xing, L.; Stass, S.A.; Jiang, F. Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing. Int. J. Cancer 2015, 136, E623–E629
182. Xu, G.; Yang, F.; Ding, C. L.; Zhao, L.J.; Ren, H.; Zhao, P.; Wang, W.; Qi, Z.T. Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma. Mol. Cancer 2014, 13, doi:10.1186/1476-4598-13-216
183. Thorenoor, N.; Slaby, O. Small nucleolar RNAs functioning and potential roles in cancer. Tumour Biol. 2015, 36, 41–53
184. Nallar, S.C.; Kalvakolanu, D.V. Regulation of snoRNAs in cancer: Close encounters with interferon. J. Interferon Cytokine Res. 2013, 33, 189–198
185. Gee, H.E.; Buffa, F.M.; Camps, C.; Ramachandran, A.; Leek, R.; Taylor, M.; Patil, M.; Sheldon, H.; Betts, G.; Homer, J., et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J. Cancer 2011, 104, 1168–1177
186. Krell, J.; Frampton, A.E.; Mirnezami, R.; Harding, V.; De Giorgio, A.; Roca Alonso, L.; Cohen, P.; Ottaviani, S.; Colombo, T.; Jacob, J., et al.Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer. PLoS ONE 2014, 9, e98561
187. Ferreira, H.J.; Heyn, H.; Moutinho, C.; Esteller, M. CpG island hypermethylation-associated silencing of small nucleolar RNAs in human cancer. RNA Biol. 2012, 9, 881–890
188. Valadkhan, S. snRNAs as the catalysts of pre-mRNA splicing. Curr. Opin. Chem. Biol. 2005, 9, 603–608
189. Baraniskin, A.; Nopel-Dunnebacke, S.; Ahrens, M.; Jensen, S.G.; Zollner, H.; Maghnouj, A.; Wos, A.; Mayerle, J.; Munding, J.; Kost, D., et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int. J. Cancer 2013, 132, E48–E57
190. Baraniskin, A.; Nopel-Dunnebacke, S.; Schumacher, B.; Gerges, C.; Bracht, T.; Sitek, B.; Meyer, H.E.; Gerken, G.; Dechene, A.; Schlaak, J.F., et al. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Dig. Dis. Sci.2014, 59, 1436–1441
191. Memczak, S.; Jens, M.; Elefsinioti, A.; Torti, F.; Krueger, J.; Rybak, A.; Maier, L.; Mackowiak, S.D.; Gregersen, L.H.; Munschauer, M., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013, 495, 333–338
192. Hansen, T.B.; Jensen, T.I.; Clausen, B.H.; Bramsen, J.B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495, 384–388
193. Chen, L.L.; Yang, L. Regulation of circRNA biogenesis. RNA Biol. 2015, 12, 381–388
194. Zhang, X.O.; Wang, H.B.; Zhang, Y.; Lu, X.; Chen, L.L.; Yang, L. Complementary sequence-mediated exon circularization. Cell 2014, 159, 134–147
195. Li, P.; Chen, S.; Chen, H.; Mo, X.; Li, T.; Shao, Y.; Xiao, B.; Guo, J. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin. Chim. Acta 2015, 444, 132–136
196. Hansen, T.B.; Kjems, J.; Damgaard, C.K. Circular RNA and miR-7 in cancer. Cancer Res. 2013, 73, 5609–5612
197. Li, F.; Zhang, L.; Li, W.; Deng, J.; Zheng, J.; An, M.; Lu, J.; Zhou, Y. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget 2015, 6, 6001–6013
198. Bachmayr-Heyda, A.; Reiner, A.T.; Auer, K.; Sukhbaatar, N.; Aust, S.; Bachleitner-Hofmann, T.; Mesteri, I.; Grunt, T.W.; Zeillinger, R., et al. Correlation of circular RNA abundance with proliferation—Exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Sci. Rep. 2015, 5, doi:10.1038/srep08057
199. Sharp, S.J.; Schaack, J.; Cooley, L.; Burke, D.J.; Soll, D. Structure and transcription of eukaryotic tRNA genes. CRC Crit. Rev. Biochem. 1985, 19, 107–144
200. Thompson, D.M.; Parker, R. Stressing out over tRNA cleavage. Cell 2009, 138, 215–219
201. Goodarzi, H.; Liu, X.; Nguyen, H.C.; Zhang, S.; Fish, L.; Tavazoie, S.F. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell 2015, 161, 790–802.